Thursday 03 December 2020

US-based clinical-stage biotech company Neurotrope, Inc. (NASDAQ: NTRP) and New Jersey based pharmaceutical company Metuchen Pharmaceuticals, L.L.C. have closed a merger announced in May to form Petros Pharmaceutical, Inc (NASDAQ: PTPI), focussed on men's health conditions, the company said.

Petros' cornerstone product would be Metuchen's Stendra for erectile dysfunction. Petros' pipeline would include Metuchen's recently in-licensed product H-100 for Peyronie's disease, and it would include a business development programme exploring various men's health products, including endothelial dysfunction, prostate cancer, psychosexual and psychosocial ailments, hormone health and substance use disorders.